Amarin Corp ADR (AMRN) Stock Price, Quote & News

Company Profile

Amarin Corporation plc, a pharmaceutical company, engages in the commercialization and development of therapeutics for the treatment of cardiovascular diseases in the United States, Europe, and internationally. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It sells its products principally through wholesalers, selected regional wholesalers, and specialty p...

Industry: Drug Manufacturers - General

Sector: Healthcare

Phone: 353 0 166 99020

Website: www.amarincorp.com

Address:

One Central Plaza, 5th Floor 36 Dame Street, Dublin, Ireland

HedgeAlerts Nov. 16 at 10:26 PM

Hedge Alert Live - Protect Your Portfolio Contract: $AMRN $16.00 Put · NOV 21, 2025 Exp Entry Price: $1.25 - $1.35 Exit Price Target: $2.82 Profit Margin: +126% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com

0 · Reply

kemah Nov. 16 at 7:31 PM

$AMRN Denner didn’t take over this company to babysit it. Cash pile. No debt. EU IP to 2039. Vazkepa growth finally showing up. U.S. generic mess contained, ex-US just getting started. This is a global CV risk asset trading like it’s dead. It’s not dead. It’s being set up for a sale. When Europe scales + a partner lands, it’s game on.

1 · Reply

DoMoreCharity Nov. 16 at 10:17 AM

$AMRN Global guideline recommended target achievements in glycaemic, blood pressure, and lipid control in type 2 diabetes: An updated meta-analysis of 1,618,972 participants Available online 15 November 2025 https://www.sciencedirect.com/science/article/abs/pii/S0168822725010162

0 · Reply

Manonsf2 Nov. 16 at 5:43 AM

$AMRN dead company for last 5 yr thanks god I sold at .45 cent and recovered my full account

4 · Reply

BobGood Nov. 16 at 1:28 AM

$AMRN I am not weighing too much on speculative takeovers as that’s totally unknown and is like a black box till it’s made public. So I don’t really worry too much about it and also I don’t want to live in paradise with high hopes. Whenever it’s destined to happen let it happen. Anyways everyone will love BO ASAP. But I like to know about Amarin Vs Hikma court case, definitely a binary event. Assume Cert is denied and assume Hikma is ready to negotiate with $AMRN to withdraw from marketing their generic, say till 2032. Now my question is whether other big players especially Reddy and Teva too will follow the suit with $AMRN to avoid hefty penalties!! If yes, that would be fantastic for the company & longs. Importantly If no, whether $AMRN will take them to courts as was with Hikma?? Any logical response is appreciated.. Wishful thinking is when major generic- Hikma, Reddy & Teva are ready for negotiation, that day will be a golden day for Longs. GL

0 · Reply

SanDiegoLiving Nov. 15 at 11:24 PM

$AMRN NOVARTIS AND AMARIN ALIGN FOR A THIRD TIME 🤝 | SARISSA RETURNS TO THE MEDCO PLAYBOOK 🧩 1️⃣ Spain Spain was the first quiet move. A national cardiovascular alliance placed AMRN beside a major portfolio name. My Breakdown: https://investorshub.advfn.com/boards/read_msg.aspx?message_id=176739314 2️⃣ GOLDEN Then came the second move. Novartis placed AMRN in the GOLDEN prevention ecosystem with timing matched to future guideline cycles. A precise alignment step. 🧪 https://clinicaltrials.gov/study/NCT06637657 3️⃣ The Third Signal 🔥 A new overseas signal quietly emerged months ago It reflects a pattern seen only when a larger framework is forming: 🧱 Institutional alignment 🏗 Top down structure 🩺 Pathway integration 🏛 National visibility 📘 Timing ahead of guidelines 👉 A clue everyone missed. The same formation Sarissa used before MedCo and the pattern Novartis acted on before pulling the trigger. 💰 Monday I drop one of my most important series putting the target squarely on NOVARTIS 🎯🎯🎯 Stay tuned! ⏳

3 · Reply

HedgeAlerts Nov. 15 at 10:28 PM

0 · Reply

LiquidThetaOptions Nov. 15 at 6:24 PM

💎 LiquidTheta® Live Actionable Trade Asset: $AMRN Contracts: $AMRN June 18, 2026 $17 Calls Scale in: $3.44- $4.21 Scale out: $13.39-$22.95 Profit Potential : 168% ROI Blended Join 💎 Here: https://liquidtheta.com

0 · Reply

Md80dog Nov. 15 at 6:02 PM

$AMRN do more charity 2016 post??? $AMRN https://investor.incyte.com/news-releases/news-release-details/incyte-and-ariad-announce-agreement-incyte-acquire-ariads

1 · Reply

BobGood Nov. 15 at 4:09 PM

$AMRN On Saturday morning with a cup of coffee on hand, it’s worth reading any forthcoming $AMRN (even if speculative in nature) news for it’s 50/50 chance for truth rather than digging or reading old (unrelated) news .. it’s boring 😴 yawning … Looking forward for any new news on $AMRN .. Saw some court news early today in iHub, any opinion from legal experts in this regard would be highly appreciated.. GL longs

0 · Reply

New REDUCE-IT® Aspirin Analysis Presented at AHA Scientific Sessions 2025 Reinforces VASCEPA®/VAZKEPA® (Icosapent Ethyl) Reduced Cardiovascular Events in High-Risk Patients

Nov 3, 2025, 8:30 AM EST - 13 days ago

Amarin To Present New Analyses Affirming Robustness of Data from REDUCE-IT and Additional Mechanisms of Action of Eicosapentaenoic Acid (EPA) at American Heart Association (AHA) Scientific Sessions 2025

Oct 29, 2025, 10:21 AM EDT - 18 days ago

Amarin Corporation plc (AMRN) Q3 2025 Earnings Call Transcript

Oct 14, 2025, 8:00 AM EDT - 4 weeks ago

Amarin and HLS Therapeutics Collaborate on Presenting REDUCE-IT® and EPA Mechanistic Data at the Canadian Cardiovascular Congress

Sep 29, 2025, 5:52 PM EDT - 6 weeks ago

Amarin: Vascepa's Global Pivot From U.S. Squeeze To International Boom

Aug 31, 2025, 8:30 AM EDT - 2 months ago

Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ESC 2025

Aug 30, 2025, 8:30 AM EDT - 2 months ago

New REDUCE-IT® Analyses Presented at ESC 2025 Include Data Showing VASCEPA®/VAZKEPA® (Icosapent Ethyl) Therapy Resulted in 9% Fewer Total Hospitalizations & Reduces Cardiovascular Disease Risk in Certain High-Risk Patient Subgroups

Aug 25, 2025, 8:00 AM EDT - 2 months ago

New Analyses from REDUCE-IT® and EPA Mechanistic Data to be Presented at the European Society of Cardiology (ESC) Congress 2025

Jul 30, 2025, 2:06 PM EDT - 3 months ago

Amarin Corporation plc (AMRN) Q2 2025 Earnings Call Transcript

Jul 30, 2025, 7:00 AM EDT - 3 months ago

Amarin Reports Second Quarter 2025 Financial Results

Jul 23, 2025, 7:30 AM EDT - 4 months ago

Amarin to Report Second Quarter 2025 Financial Results and Host Conference Call on July 30, 2025

Jun 24, 2025, 7:05 AM EDT - 5 months ago

RECORDATI ANNOUNCES EXCLUSIVE LICENSING & SUPPLY AGREEMENT WITH AMARIN TO COMMERCIALIZE VAZKEPA® IN EUROPE

May 7, 2025, 11:01 AM EDT - 6 months ago

Amarin Corporation plc (AMRN) Q1 2025 Earnings Call Transcript

Apr 29, 2025, 4:15 PM EDT - 7 months ago

Amarin Regains Compliance with Nasdaq Minimum Bid Price Requirement

Apr 28, 2025, 4:15 PM EDT - 7 months ago

Amarin to Report First Quarter 2025 Financial Results and Host Conference Call on May 7, 2025

Apr 14, 2025, 10:02 AM EDT - 7 months ago

Hyatt Hotels, THOR Industries And Other Big Stocks Moving Lower On Monday

H THO ALMS CCO ECX HZO NUTX

Apr 9, 2025, 7:30 AM EDT - 7 months ago

Amarin Confirms Effective Date for 1-For-20 ADS Ratio Change

Apr 7, 2025, 7:30 AM EDT - 7 months ago

Amarin Appoints JEC Capital Partners' Michael Torok to Board of Directors

Mar 19, 2025, 12:45 PM EDT - 8 months ago

Concerned Shareholder Group Urges Amarin's Board of Directors to Initiate a Strategic Review Following Two Years of Underperformance

Mar 19, 2025, 7:30 AM EDT - 8 months ago

New Research Exploring Mechanistic Benefits of Eicosapentaenoic Acid (EPA) In Vitro on Lipoprotein(a) [Lp(a)] Oxidation and on Protein Expression in Endothelial Cells in Combination with GLP-1 Receptor Agonist to be Presented at the American College of Cardiology's (ACC) Annual Scientific Session & Expo

Mar 12, 2025, 10:30 AM EDT - 8 months ago

Amarin Corporation plc (AMRN) Q4 2024 Earnings Call Transcript

Feb 27, 2025, 9:00 AM EST - 9 months ago

Amarin Marks Key Milestone for VASCEPA®/VAZKEPA® (Icosapent Ethyl) -- Publication of Post Hoc Analysis of REDUCE-IT in Journal of the American Heart Association Reports Benefit on Top of Cholesterol Lowering

Feb 19, 2025, 8:30 AM EST - 9 months ago

Amarin to Report Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on March 12, 2025

Dec 16, 2024, 7:00 AM EST - 11 months ago

Amarin Receives National Reimbursement for VAZKEPA® in Italy

Dec 13, 2024, 9:00 AM EST - 1 year ago

Amarin Appoints Peter Fishman Chief Financial Officer

Nov 19, 2024, 7:52 AM EST - 1 year ago

Top 3 Health Care Stocks You'll Regret Missing In Q4

SLN TERN

Oct 30, 2024, 8:50 PM EDT - 1 year ago

Amarin Corporation plc (AMRN) Q3 2024 Earnings Call Transcript

Sep 9, 2024, 7:30 AM EDT - 1 year ago

Research Highlighting the Clinical Impact of VASCEPA®/VAZKEPA (icosapent ethyl) in Patients with Diabetes and High Cardiovascular Risk and the Anti-Lp(a) Oxidation Mechanistic Effect of Eicosapentaenoic Acid (EPA) to be Presented at the 60th Annual European Association for the Study of Diabetes (EASD) Meeting

Aug 22, 2024, 8:30 AM EDT - 1 year ago

Latest Research Highlighting VASCEPA®/VAZKEPA® (icosapent ethyl) REDUCE-IT® Subgroup Data and New Mechanistic Insights into Eicosapentaenoic Acid (EPA) to be Presented at European Society of Cardiology (ESC) Congress

Jul 31, 2024, 12:28 PM EDT - 1 year ago

Amarin Corporation plc (AMRN) Q2 2024 Earnings Call Transcript

Jul 31, 2024, 7:00 AM EDT - 1 year ago

Amarin Reports Second Quarter 2024 Financial Results and Provides Business Update

Jul 17, 2024, 4:15 PM EDT - 1 year ago

Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Portugal

Jul 17, 2024, 8:00 AM EDT - 1 year ago

Amarin to Report Second Quarter 2024 Financial Results and Host Conference Call on July 31, 2024

Jul 8, 2024, 7:30 AM EDT - 1 year ago

Amarin Partner EddingPharm Receives Regulatory Approval for VASCEPA® (Icosapent Ethyl) in Mainland China for Cardiovascular Risk Reduction (CVRR)

Jun 7, 2024, 7:16 PM EDT - 1 year ago

LA BOUTIQUE Opens Flagship Store at Gaysorn Amarin: The New Must-Visit Destination in Bangkok

Jun 4, 2024, 7:30 AM EDT - 1 year ago

Amarin Board of Directors Announces CEO Transition

May 28, 2024, 8:15 AM EDT - 1 year ago

Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Greece and Announces Exclusive Marketing and Commercialization Agreement with Vianex S.A.

May 6, 2024, 8:00 AM EDT - 1 year ago

Amarin to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference

May 1, 2024, 10:43 AM EDT - 1 year ago

Amarin Corporation plc (AMRN) Q1 2024 Earnings Call Transcript

May 1, 2024, 7:00 AM EDT - 1 year ago

Amarin Reports First Quarter 2024 Business Update and Financial Results

Apr 24, 2024, 2:00 PM EDT - 1 year ago

Amarin Applauds HealthyWomen's Citizen's Petition Urging FDA To Take Further Action On Fenofibrate Prescribing in Patients at Risk of Cardiovascular Event

Apr 22, 2024, 8:00 AM EDT - 1 year ago

Amarin Announces Results of Annual General Meeting of Shareholders

Apr 15, 2024, 8:00 AM EDT - 1 year ago

Amarin to Report First Quarter 2024 Financial Results and Host Conference Call on May 1, 2024

Apr 8, 2024, 8:00 AM EDT - 1 year ago

Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ACC.24

Apr 6, 2024, 3:30 PM EDT - 1 year ago

New REDUCE-IT® Analyses Show VASCEPA®/VAZKEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups

Apr 3, 2024, 8:00 AM EDT - 1 year ago

Amarin Provides Update on VAZKEPA® (Icosapent Ethyl) Intellectual Property Portfolio in Europe

Mar 25, 2024, 8:00 AM EDT - 1 year ago

Research Evaluating Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the American College of Cardiology's (ACC) Annual Scientific Session & Expo

Feb 29, 2024, 10:18 AM EST - 1 year ago

Amarin Corporation plc (AMRN) Q4 2023 Earnings Call Transcript

Feb 29, 2024, 7:00 AM EST - 1 year ago

Amarin Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Feb 15, 2024, 8:00 AM EST - 1 year ago

Amarin to Report Fourth Quarter and Full Year 2023 Financial Results and Host Conference on February 29, 2024

HedgeAlerts Nov. 16 at 10:26 PM

0 · Reply

kemah Nov. 16 at 7:31 PM

1 · Reply

DoMoreCharity Nov. 16 at 10:17 AM

0 · Reply

Manonsf2 Nov. 16 at 5:43 AM

$AMRN dead company for last 5 yr thanks god I sold at .45 cent and recovered my full account

4 · Reply

BobGood Nov. 16 at 1:28 AM

0 · Reply

SanDiegoLiving Nov. 15 at 11:24 PM

3 · Reply

HedgeAlerts Nov. 15 at 10:28 PM

0 · Reply

LiquidThetaOptions Nov. 15 at 6:24 PM

0 · Reply

Md80dog Nov. 15 at 6:02 PM

$AMRN do more charity 2016 post??? $AMRN https://investor.incyte.com/news-releases/news-release-details/incyte-and-ariad-announce-agreement-incyte-acquire-ariads

1 · Reply

BobGood Nov. 15 at 4:09 PM

0 · Reply

DoMoreCharity Nov. 15 at 3:21 PM

$AMRN https://investor.incyte.com/news-releases/news-release-details/incyte-and-ariad-announce-agreement-incyte-acquire-ariads

1 · Reply

CaptBeer Nov. 14 at 9:04 PM

BEER GOOD $AMRN GOOD! Have a great WEEKEND everyone!

1 · Reply

JB2223 Nov. 14 at 7:07 PM

$AMRN are we sure we aren’t all just characters of Lost? Lost: AMRN Shareholders edition

0 · Reply

HedgeAlerts Nov. 14 at 6:12 PM

Hedge Alert Live - Protect Your Portfolio Contract: $AMRN $16.00 Put · NOV 21, 2025 Exp Entry Price: $0.90 - $1.25 Exit Price Target: $2.49 Profit Margin: +99% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com

0 · Reply

LiquidThetaOptions Nov. 14 at 6:02 PM

💎 LiquidTheta® Live Actionable Trade Asset: $AMRN Contracts: $AMRN June 18, 2026 $17 Calls Scale in: $3.48- $4.25 Scale out: $13.52-$23.17 Profit Potential : 84% ROI Blended Join 💎 Here: https://liquidtheta.com

0 · Reply

BobGood Nov. 14 at 5:43 PM

$AMRN Looks like Canada (smaller than CA), is generating more revenues than total EU so far. Hopefully EU should dramatically increase their revenues after Recordati takeover starting from this Q4 or at least from Q1, 2026 which is long overdue from investors perspective!! GL

0 · Reply

CEVIN Nov. 14 at 3:01 PM

$AMRN Just to give context on the HLS sales since it launched Vascepa in Canada in 2020….Wonder how Europe will do by 2030 ?

1 · Reply

DoMoreCharity Nov. 14 at 12:21 PM

$AMRN https://www.ainvest.com/news/hls-therapeutics-narrowing-loss-accelerating-path-profitability-2511/

0 · Reply

HedgeAlerts Nov. 14 at 7:31 AM

Hedge Alert Live - Protect Your Portfolio Contract: $AMRN $16.00 Put · NOV 21, 2025 Exp Entry Price: $1.00 - $1.25 Exit Price Target: $2.70 Profit Margin: +116% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com

0 · Reply

Md80dog Nov. 14 at 12:11 AM

$AMRN investors have forgotten the old saying: Revenue is vanity, profits are sanity, cash is reality.

0 · Reply

SanDiegoLiving Nov. 13 at 10:27 PM

$AMRN 🔥HLS Q3 QUIETLY BOOSTING AMARIN'S FUTURE BUYOUT MATH 🇨🇦💼 HLS reported Q3 results and the call revealed a major shift in Vascepa’s strength in Canada. Demand increased with +22% Q3 unit growth and +24%year to date. Physicians expanded usage with +29% growth in consistent prescribers and new patient starts rising every month in the quarter. 💰 Profit confirmation Vascepa generated $600,000 in Adjusted EBITDA, its first profitable quarter in Canada. FX and a growing public payer mix reduced reported revenue but did not affect underlying volume. 🔥 Why this matters for M&A A partner market showing rising demand and positive product level profit lowers risk for any buyer modeling global revenue durability. 🔒 Exclusivity through 2039 A long patent window strengthens valuation. 🔭 Forward read HLS Q3 supports a more stable ex US profile for Vascepa, improving Amarin’s position in upcoming strategic review conversations.

2 · Reply

declanaidan Nov. 13 at 9:04 PM

$AMRN At least green today in a dismal overall market. Volume at three month average of about 100k shares

0 · Reply

Market Cap	339.76M
Revenue (ttm)	228.61M
Net Income (ttm)	-82.18M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	406.75
Profit Margin	-35.95%
Debt to Equity Ratio	0.00

Volume	82,500
Avg Vol	112,828
Day's Range	N/A - N/A
Shares Out	20.79M
Stochastic %K	81%
Beta	0.68
Analysts	Buy
Price Target	$11.33